News
The day at a glance · 3 min read
Mood · Cautious
+15
Sentiment, −100 to +100
Merck Pipeline Value Target
$70B
AbbVie Apogee Acquisition
$10.9B
BMY Dividend Yield
4.58%
Key driverMajor pharma companies accelerating pipeline investment and M&A activity ahead of blockbuster patent expirations
Daily briefHealthcare· Money365.Market AI ·

Big Pharma Preps for Patent Cliff as M&A Heats Up

Merck targets $70B pipeline rebuild, AbbVie closes $10.9B Apogee deal, UnitedHealth turnaround gains momentum

Big Pharma & Biotech

Neutral

Eli Lilly Stock Gain (1Y)

56%
MRKABBVAPGEBMYNVSGILDLLY
Merck & Co. (MRK) has increased its estimated pipeline value to $70B as the company prepares for the eventual loss of exclusivity for KEYTRUDA, according to Chief Financial Officer Caroline Litchfield speaking at an investor conference. The strategy centers on pipeline investment, new product launches and targeted business development to offset the blockbuster cancer drug's patent cliff.
AbbVie Inc. (ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (APGE) for $135.11 per share in cash on September 3, a $10.9 billion transaction that immediately integrates Apogee's inflammatory and immunology pipeline into AbbVie's commercial operations. On the same day, AbbVie separately reported positive Phase 3 Cervino trial results for its own pipeline assets.
Bristol-Myers Squibb (BMY) has cleared ChartMill's Best Dividend Stocks screen with a 4.58% yield, though high payout ratios and falling earnings raise sustainability concerns for the dividend. The pharmaceutical sector faced major pipeline setbacks on September 1 when Novartis AG (NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy, following three patient deaths caused by severe immune reactions.
Gilead Sciences (GILD) Chief Medical Officer Dietmar Berger outlined the company's priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritization and execution.
Eli Lilly (LLY) stock has gained 56% over the past year, moving from $722.65 to $1,123.91, following a period in which the company deliberately limited sales of certain medicines below market demand while building manufacturing capacity.

Biopharma Ratings & Valuation

Neutral

Amgen Share Price

$393

Amgen Trailing P/E Multiple

23.3x
NVSAMGN
HSBC adjusted ratings and target prices across its biopharma coverage, citing a lower sector additional risk premium following a rally in the second quarter of 2026, with the firm lifting Novartis (NVS) and downgrading Amgen (AMGN). Despite the downgrade, one analyst upgraded Amgen stock to buy, arguing the company raised full-year 2026 revenue and EPS guidance, signaling improved confidence.
Amgen (AMGN) trades at about $393 per share, representing a trailing multiple of about 23.3 times on the last twelve months of adjusted earnings. With Prolia and XGEVA sales falling to biosimilar rivals, the valuation appears demanding unless the company can deliver wider margins while funding its MariTide obesity drug program.

Health Insurance & Managed Care

Bullish

UNH Prior Auth Reduction Target

30%
UNHCVS
UnitedHealth Group (UNH) executives said the company's turnaround remained on track, citing continued strength in Medicare Advantage, Medicaid performance tracking toward the favorable end of expectations, and operational improvements at Optum Health. The company's insurance unit is removing prior-authorization requirements from a broad range of healthcare services beginning October 1, part of UnitedHealthcare's plan to eliminate such requirements for 30% of healthcare services by the end of 2026.
CVS Health (CVS) executives said the company is seeing improved momentum across its insurance, pharmacy, care delivery and balance-sheet priorities, while maintaining a cautious outlook on healthcare cost trends and several 2027 headwinds. Chief Financial Officer remarks at an investor conference highlighted margin recovery and cash flow priorities heading into next year.

MedTech & Devices

Neutral

ISRG Stock Decline (12M)

25%

China Psoriasis Market

8.4M
ISRGJNJ
Intuitive Surgical (ISRG) stock is down 25% over the trailing twelve months while the S&P 500 returned 19.3%, and it now trades about 41% below its 52-week high. After a significant decline, options priced a year out suggest substantial volatility remains ahead for the surgical robotics leader.
Johnson & Johnson (JNJ) has secured Chinese approval for Icotyde, its once-daily oral treatment for moderate-to-severe plaque psoriasis, providing another route into a market where more than 8.4 million people are affected by psoriasis according to the company. Icotyde could appeal to patients who prefer a pill over an injectable treatment in a growing market for dermatology therapies.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy